# T-Therapeutics

> Cambridge biotechnology company developing T-cell receptor bispecific medicines for cancer and autoimmune disease.

## Why it is interesting

Announced a $133M Series B co-led by Advent Life Sciences and British Business Bank on November 5, 2026; developing OpTiMus TCR discovery and T-Bridge TCR-CD3-Fc bispecific programs.

## Profile

- **Latest funding:** Series B — $133M (November 5, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $224M
- **Stage:** growth
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-06
- **Latest funding investors:** Advent Life Sciences, British Business Bank, Samsara BioCapital, M-Ventures, Eli Lilly

## Funding history

- Series B · $133M · November 5, 2026
  Source: https://rss.globenewswire.com/news-release/2026/11/05/3396064/0/en/t-therapeutics-announces-oversubscribed-133-million-series-b-financing-to-achieve-clinical-proof-of-concept-for-first-in-class-tcr-bispecific-therapies-in-cancer-and-autoimmune-dis.html
- Series A extension, incremental · $32M; total Series A $91M · November 13, 2025
  Source: https://t-therapeutics.com/t-therapeutics-announces-series-a-extension-to-91-million-to-advance-first-in-class-bispecifics-towards-the-clinic/
- Series A initial · $59M · November 15, 2023
  Source: https://t-therapeutics.com/t-therapeutics-raises-48-million-series-a-for-development-of-next-generation-tcr-therapeutics-to-transform-cancer-treatment/

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 6, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/t-therapeutics